Close Menu

Breaking News

Illumina said it plans to "vigorously defend" the deal and oppose the FTC, which previously helped scuttle Illumina's proposed acquisition of Pacific Biosciences.

The 30-minute test can be used on samples from males and females in settings operating under a CLIA certificate of waiver.

Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.

Osang previously granted nonexclusive US distribution rights to the PCR-based test to SG Blocks and has a manufacturing arrangement for the test with Nexus Dx.

Concentric by Ginkgo has been partnering with labs across the US in more than 15 states to run testing for schools offering in-person education.

Proscia said that Unilabs will use its suite of artificial intelligence applications to implement computational pathology into routine pathology workflows.

The agency said that an individual involved in a urine testing kickback had agreed to a settlement, while a defendant in a genetic testing fraud case plead guilty.

The firm's fourth quarter revenues included $18.3 million in commercial test revenue, of which $17.6 million was attributable to COVID-19 tests.

The technology, called UAL-Chip, uses microfluidic technology to test for levels of albumin in urine and deliver rapid results to a user's smartphone.

Following the transaction, which values the company at roughly $1.2 billion and will provide cash proceeds of around $650 million, SomaLogic will list on the Nasdaq.

The study will evaluate the emergence of biomarkers that are indicators for autoimmune diseases and assess these biomarkers in mild and moderate COVID-19 patients.

Amazon said that it will use its test for employees and other individuals who enter its facilities as part of its COVID-19 preparedness and response program.

Last week, readers were most interested in Rockefeller Foundation's partnership with test developers to do COVID-19 testing in schools.

Visby's single-use, fully integrated assay is designed to detect SARS-CoV-2 nucleic acid in samples collected either by a healthcare provider or self-collected.

The Korean molecular diagnostics firm, a spinoff from genomic services provider Macrogen, also announced plans for an IPO early next year.

Before launching its COVID-19 test, which generated most of Co-Diagnostics' revenues in 2020, the firm's sales primarily came from mosquito-borne virus testing.

The labs will provide testing for K-12 schools by testing each consenting person in a classroom as one pool.

News items for the in vitro diagnostics industry for the week of March 22, 2021.

For the year ended Dec. 31, 2020, the firm reported revenues of $8.5 million compared to $19.2 million in 2019, beating the Wall Street estimate of $8.3 million. 

The agreement is with the Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz.

The company's full-year revenues were $4.2 million, up 20 percent from the year-ago quarter.

The company's fourth quarter 2020 revenues were buoyed by sales of its SARS-CoV-2 testing-related products including transport media.

The organization's report is a roadmap to implement the funds from President Biden's $10 billion allocation toward routine school testing for SARS-CoV-2.

The company reported RMB133.9 million (US$20.5 million) for the quarter, up from RMB102.9 million in the same period of 2019.

The firm said that due to a negative coverage decision and capital constraints, it is evaluating options including a sale by a public takeover or an asset deal.